New EU Approvals
Executive Summary
The Pink Sheet’s list of EU centralized approvals of new active substances now includes three new products including Janssen's Erleada, a next generation oral androgen receptor inhibitor for treating adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (e.g., medicine, vaccine, biologic).
You may also be interested in...
COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs And Tests
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
EMA Issues Guidance On Compassionate Use Of Remdesivir For COVID-19
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: